Ngm Biopharmaceuticals Inc (NGM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 4,417 | 55,333 | 77,882 | 87,368 | 103,544 |
| Gross Profit | 4,417 | 55,333 | 77,882 | 87,368 | 103,544 |
| Operating Expenses | 155,880 | 221,582 | 198,577 | 191,201 | 152,884 |
| Operating Income | -151,463 | -166,249 | -120,695 | -103,833 | -49,340 |
| Other Income | 9,088 | 3,582 | 360 | 1,346 | 6,545 |
| Pre-tax Income | -142,375 | -162,667 | -120,335 | -102,487 | -42,795 |
| Net Income Continuous | -142,375 | -162,667 | -120,335 | -102,487 | -42,795 |
| Net Income | $-142,375 | $-162,667 | $-120,335 | $-102,487 | $-42,795 |
| EPS Basic Total Ops | -1.73 | -2.03 | -1.56 | -1.50 | -0.85 |
| EPS Basic Continuous Ops | -1.73 | -2.03 | -1.56 | -1.50 | -0.85 |
| EPS Diluted Total Ops | -1.73 | -2.03 | -1.56 | -1.50 | -0.85 |
| EPS Diluted Continuous Ops | -1.73 | -2.03 | -1.56 | -1.50 | -0.85 |
| EPS Diluted Before Non-Recurring Items | -1.73 | -2.03 | -1.56 | -1.50 | -0.85 |
| EBITDA(a) | $-154,794 | $-162,145 | $-111,092 | $-97,406 | $-42,858 |